Dr Varun Kapoor, Coherus BioSciences, will present on "CHS-114: A Highly Selective Cytolytic CCR8 Monoclonal Antibody Treatment in HNSCC Patients with and without Toripalimab" at the 11th annual #IO360Summit. This session will delve into Coherus Biosciences' innovative CHS-114, a highly selective cytolytic CCR8 monoclonal antibody for head and neck squamous cell carcinoma (HNSCC). CHS-114 preferentially targets and depletes tumor-resident Treg cells, which aims to avoid the toxicity and autoimmunity seen with broader Treg depletion. Clinical data will be presented on its use alone and with toripalimab, showcasing its proof of mechanism, efficacy and safety in overcoming challenges in Treg-targeted cancer therapies. Learn more at IO360Summit.com
Coherus BioSciences
生物技术研究
Redwood City，CA 35,920 位关注者
We are in the business of extending life for patients.
关于我们
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at https://www.coherus.com/careers/ for a list of career opportunities.
- 网站
-
https://www.coherus.com
Coherus BioSciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Redwood City，CA
- 类型
- 上市公司
- 创立
- 2010
- 领域
- biotechnology、biosimilars和Immuno-oncology
地点
Coherus BioSciences员工
动态
-
Coherus' Chief Development Officer, Theresa LaVallee, PhD, is participating in a panel session on "Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies" at the 11th #IO360Summit in Boston next week. This session will guide biotechs through IO drug development amidst a saturated landscape and delve into tailored approaches for IO-focused companies, addressing challenges and charting pathways for successful advancement in the field.
Dr Priti Hegde, Kite Pharma, will moderate a panel session on "Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies" at the 11th Annual IO360o Summit. This session will guide biotechs through IO drug development amidst a saturated landscape and delve into tailored approaches for IO-focused companies, addressing challenges and charting pathways for successful advancement in the field. Panelists include: ? Dr Roy Baynes, Eikon Therapeutics ? Dr Sharon Benzeno, Adaptive Biotechnologies Corp. ? Dr Rachel Humphrey, Normunity ? Dr Theresa LaVallee, Coherus BioSciences ?? Learn more at IO360Summit.com #IO360Summit #IO360 #immunooncology
-
-
Attending #IO360Summit? Meet with Coherus’ Chief Development Officer, Theresa LaVallee and EVP, Corporate Development, Scott Saywell to learn more about the exciting developments in our novel oncology pipeline. We look forward to seeing you in Boston!
-
-
Dr Theresa LaVallee, Chief Development Officer of Coherus BioSciences, recently shepherded their drug toripalimab through a challenging approval process. She tells us what is next for the drug, the challenges facing medicine developers, and what keeps her enthusiastic about immuno-oncology. ?? Read the interview here: https://lnkd.in/eb-ty6dn #IO360Summit
-
-
Join us for our Q4-FY 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q4 financial results and recent business highlights. Press release: https://bit.ly/41DvYa7 and Listen to the webcast: https://bit.ly/4hlVgQ9
-
-
Coherus will report Q4 and Full Year 2024 financial results on March 10, 2025. Starting at 5 pm EST, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q4-FY 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4hlVgQ9
-
-
Coherus will report Q4 and Full Year 2024 financial results on March 10, 2025. Starting at 5 pm EST, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q4-FY 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4hlVgQ9
-
-
Coherus CEO?Denny Lanfear?and Chief Development Officer?Theresa LaVallee?will participate in a fireside chat presentation with?Michael Nedelcovych?at?TD Securities?Cowen Health Care Conference on Tuesday, March 4th at 11:50 am ET. Listen in via webcast: https://lnkd.in/gsxG8k8y
-
-
Coherus presented final results from our Phase 2 HCC study of casdozo in combination with atezo/bev at ASCO#GI25 today. View the poster here: https://bit.ly/40KERQ4
-
-
We look forward to Dr. Denang Li’s presentation of the final data from our Phase 2 combination study of casdozo with standard of care in patients with liver cancer on Friday at the 2025 American Society of Clinical Oncology (ASCO) GI Symposium. Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate the durability of response and improvement in the depth of response, including a 17.2% complete response rate. Read more about the data and the upcoming presentation in our press release: https://bit.ly/3PL5myo
-